{"gene":"TAT","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":1990,"finding":"HIV-1 Tat protein binds selectively to TAR RNA in vitro with specificity mapping to the single-stranded 'bulge' region of the TAR stem-loop; the basic region of Tat is sufficient for TAR RNA binding, forming a one-to-one complex with Kd ~12 nM. Mutations in the bulge reduced affinity 6-10 fold, while loop mutations did not affect Tat binding.","method":"In vitro RNA-binding assay with bacterially expressed Tat protein and synthetic TAR RNA; competition assays with TAR mutants; Scatchard analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, replicated across multiple labs (PMID:2247474 and PMID:1903308)","pmids":["2247474","1903308"],"is_preprint":false},{"year":1991,"finding":"Tat activates HIV transcription primarily by enhancing transcriptional elongation rather than initiation; a minimal Tat activation domain of ~47 amino acids (HIV-1) or 15 amino acids (EIAV) is sufficient to stimulate processivity of transcription complexes when tethered to nascent RNA. The RNA-binding domain (~10 aa) and activation domain are separable functional modules.","method":"Protein fusion experiments tethering Tat activation domains to heterologous RNA-binding domains (bacteriophage R17 coat protein); transcriptional assays on LTR reporters","journal":"Journal of virology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution using domain-swap and tethering experiments, replicated across multiple studies (PMID:1658392, PMID:1752440)","pmids":["1658392","1752440"],"is_preprint":false},{"year":1991,"finding":"Tat can function when bound to upstream promoter DNA rather than TAR RNA; the activation domain required for RNA-bound Tat is also required for DNA-bound Tat, but the arginine-rich RNA-binding domain is dispensable for DNA-bound Tat function. Tat activity requires cooperation with promoter-bound cellular transcription factors in both contexts.","method":"Protein fusion experiments with GAL4 DNA-binding domain; transcriptional reporter assays; domain mutagenesis","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — reconstitution with domain mutagenesis, single lab","pmids":["1752440"],"is_preprint":false},{"year":1996,"finding":"Tat-SF1 is a cellular cofactor required for Tat transactivation; it associates with a cellular kinase and is a substrate of that kinase. Tat-SF1 contains two RNA recognition motifs and an acidic C-terminal half. Co-transfection of Tat-SF1 cDNA specifically modulates Tat activation, and Tat-SF1 functions as a general transcription elongation factor.","method":"cDNA isolation by functional complementation; co-transfection transcriptional assays; protein-affinity chromatography; immunodepletion and complementation with recombinant proteins","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including functional complementation, immunodepletion, and affinity chromatography across two studies (PMID:8849451, PMID:9765201)","pmids":["8849451","9765201"],"is_preprint":false},{"year":1999,"finding":"Tat stimulates transcriptional elongation by recruiting the TAK (Tat-associated kinase) complex, which contains CDK9 and cyclin T1 (P-TEFb), to the transcription machinery via TAR RNA. This results in hyperphosphorylation of the RNA polymerase II CTD. Cyclin T1 participates in TAR RNA recognition and enables Tat to form a ternary complex with TAR RNA only when a functional loop sequence is present, explaining why loop mutations abolish Tat activity in vivo but not Tat-TAR binding in vitro.","method":"Dominant-negative CDK9 kinase inhibition assays; kinase inhibitor studies; ternary complex formation assays with cyclin T1 and TAR RNA loop mutants","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (dominant-negative mutants, kinase inhibitors, RNA-protein complex assays), replicated across labs","pmids":["10550206"],"is_preprint":false},{"year":1999,"finding":"HIV-1 Tat is directly acetylated at two distinct sites by two different HATs: p300 acetylates Lys50 in the TAR RNA binding domain, and PCAF acetylates Lys28 in the activation domain. Acetylation at Lys28 by PCAF enhances Tat binding to CDK9/P-TEFb, while acetylation at Lys50 by p300 promotes dissociation of Tat from TAR RNA during transcription elongation.","method":"In vitro acetylation assays; site-directed mutagenesis of Lys28 and Lys50; co-immunoprecipitation; transcriptional activation assays; trichostatin A synergy experiments","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro acetylation with mutagenesis plus functional transcription assays and co-IP, multiple orthogonal methods in one study","pmids":["10545121"],"is_preprint":false},{"year":1998,"finding":"Tat-SF1 associates with RAP30 (a subunit of TFIIF) and human SPT5 (hSPT5) in nuclear extracts; immunodepletion of Tat-SF1 abolishes Tat activation which is rescued by recombinant Tat-SF1; overexpression of Tat-SF1 and hSPT5 specifically stimulates Tat transcriptional activity in vivo. RAP74 subunit of TFIIF is not co-immunoprecipitated with Tat-SF1.","method":"Co-immunoprecipitation from nuclear extracts; immunodepletion with complementation; overexpression assays; transcriptional activation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, immunodepletion/rescue, and functional overexpression across multiple orthogonal methods","pmids":["10454543"],"is_preprint":false},{"year":1999,"finding":"HIV-1 Tat protein mimics beta-chemokines: it induces rapid transient Ca2+ influx in monocytes/macrophages via pertussis toxin-sensitive receptors, causes monocyte migration, and cross-desensitizes with MCP-1, MCP-3, and eotaxin. Tat displaces beta-chemokines from receptors CCR2 and CCR3 (but not CCR1, CCR4, CCR5), and a Tat peptide (CysL24-51) directly binds cells transfected with CCR2 and CCR3.","method":"Ca2+ influx assays; monocyte migration assays; cross-desensitization studies; competitive receptor binding displacement; direct binding to CCR2/CCR3-transfected cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Ca2+ flux, migration, receptor binding, cross-desensitization) in a single rigorous study","pmids":["9789057"],"is_preprint":false},{"year":1999,"finding":"Tat-induced neuronal apoptosis involves activation of glycogen synthase kinase-3beta (GSK-3beta); Tat co-precipitates with GSK-3beta but direct addition of Tat to purified GSK-3beta has no effect on enzyme activity, indicating Tat's effects on GSK-3beta are indirect. PAF receptor activation also activates GSK-3beta. Lithium (GSK-3beta inhibitor) enhances neuronal survival after Tat exposure.","method":"GSK-3beta kinase activity assays; co-precipitation; lithium treatment rescue experiments; PAF receptor activation studies in rat cerebellar granule neurons","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-precipitation plus enzymatic activity assays plus pharmacological rescue, single lab","pmids":["10428053"],"is_preprint":false},{"year":2002,"finding":"Transcriptional synergy between Tat and PCAF requires acetylation of Lys50 of Tat and the PCAF bromodomain. Structural analysis defined critical interaction residues: Y47 and R53 in Tat, and V763, Y802, Y809 in PCAF bromodomain. Mutation of these residues inhibits Tat-PCAF interaction in vitro and in vivo and abrogates HIV promoter synergistic activation.","method":"In vitro and in vivo binding assays; structural analysis of acetylated Tat peptide bound to PCAF bromodomain; site-directed mutagenesis; HIV promoter transactivation assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural data combined with mutagenesis and functional transcription assays, multiple orthogonal methods","pmids":["12032084"],"is_preprint":false},{"year":2002,"finding":"Tat stimulates cotranscriptional capping of HIV mRNA; this stimulation requires the C-terminal segment of Tat that mediates direct binding to the capping enzyme Mce1. Both Mce1 and the cap methyltransferase Hcm1 travel with Pol II during elongation and require CTD phosphorylation for stable binding to template-engaged Pol II.","method":"In vitro transcription/capping assays with template-engaged Pol II; domain deletion studies identifying C-terminal Tat-Mce1 binding region; cotranscriptional capping efficiency measurements","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with defined domain requirements, single lab but multiple orthogonal approaches","pmids":["12408826"],"is_preprint":false},{"year":2005,"finding":"Tat is deacetylated by SIRT1, a NAD-dependent class III deacetylase, in vitro and in vivo; Tat and SIRT1 co-immunoprecipitate and synergistically activate the HIV promoter. Knockdown of SIRT1 or treatment with SIRT1 inhibitors inhibit Tat-mediated transactivation. Tat transactivation is defective in SIRT1-null MEFs and rescued by SIRT1 re-expression. SIRT1 recycles Tat to its unacetylated form to enable repeated rounds of transcription.","method":"In vitro deacetylation assays; co-immunoprecipitation; siRNA knockdown; SIRT1-null MEF rescue experiments; HIV LTR transactivation assays","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro enzymatic assay plus co-IP plus genetic null rescue, multiple orthogonal methods in single study","pmids":["15719057"],"is_preprint":false},{"year":2005,"finding":"Tat protein directly enhances tubulin polymerization; residues 38-72 of Tat are responsible for this activity. Tat can also directly trigger the mitochondrial apoptosis pathway, as evidenced by release of cytochrome c from isolated mitochondria in vitro.","method":"Tubulin polymerization assays with recombinant Tat variants and truncation peptides; cytochrome c release assays from isolated mitochondria; comparison with paclitaxel","journal":"Retrovirology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution assays with defined peptide domains, single lab","pmids":["15691386"],"is_preprint":false},{"year":2005,"finding":"Tat interacts with LIS1, a microtubule-associated protein, in vitro and in vivo. LIS1 was identified during biochemical fractionation of T-cell extracts co-purifying with Tat-associated RNAPII CTD kinase activity. Tat-LIS1 interaction was confirmed by co-IP in HeLa cells and yeast two-hybrid. Tat did not interact directly with CDK7, cyclin H, or MAT1 that co-purify in the same fractions.","method":"Biochemical fractionation of T-cell extracts; in vitro binding assay; co-immunoprecipitation from HeLa cells; yeast two-hybrid","journal":"Retrovirology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods including co-IP, in vitro binding, and yeast two-hybrid; single lab","pmids":["15698475"],"is_preprint":false},{"year":2005,"finding":"HEXIM1 inhibits Tat transactivation by regulating P-TEFb activity; HEXIM1-mediated repression requires both its 7SK snRNA basic recognition motif and the C-terminal region required for cyclin T1 interaction. HEXIM1 expression specifically represses transcription mediated by direct activation of P-TEFb through artificial recruitment of GAL4-CycT1, and this repression is not due to global inhibition of cellular transcription.","method":"Co-expression transcriptional repression assays; HEXIM1 domain mutant analysis; GAL4-CycT1 artificial recruitment assay; HIV LTR reporter assays","journal":"Retrovirology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional domain mutagenesis with multiple reporter systems, single lab","pmids":["15992410"],"is_preprint":false},{"year":1997,"finding":"Tat is required for efficient HIV-1 reverse transcription; HIV-1 virions deleted in tat cannot initiate reverse transcription efficiently in PBMCs, despite containing normal levels of genomic RNA, reverse transcriptase, and other viral proteins. Complementation of tat in producer cells (not target cells) rescues the reverse transcription defect, and tat-deleted virions also show defects in endogenous reverse transcription assays.","method":"Tat-deleted HIV-1 virion production; infection of PBMCs with complementation in producer vs. target cells; endogenous reverse transcription assays; protein and RNA quantification of virion components","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic complementation with defined producer/target cell distinction, multiple assays establishing the reverse transcription defect","pmids":["9135139"],"is_preprint":false},{"year":1995,"finding":"The structure of HIV-1 Tat protein in solution was determined by 2D NMR and molecular dynamics; the protein exhibits a hydrophobic core of 16 amino acids, a glutamine-rich domain of 17 amino acids, a cysteine-rich domain, and a basic sequence region. The basic and cysteine-rich domains are highly flexible. The C-terminal region contains an RGD loop structurally similar to that of decorsin.","method":"2D NMR spectroscopy; molecular dynamics calculations","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure determination with MD validation, single lab but rigorous structural method","pmids":["7723010"],"is_preprint":false},{"year":2008,"finding":"HIV-1 Tat (clade B) binds directly to the NMDA receptor (NR1 subunit) leading to excitotoxicity; the Cys30-Cys31 motif in Tat is critical for NMDA receptor activation. Through molecular modeling and site-directed mutagenesis, Cys31 is predicted to disrupt the disulfide bond between Cys744 and Cys798 on NR1 by interacting with Cys744, leaving a free thiol on Cys798 and causing persistent NMDA receptor activation. The Cys31Ser mutation in clade C Tat significantly attenuates neurotoxicity.","method":"Direct Tat-NMDA receptor binding experiments; site-directed mutagenesis (Cys31Ser); molecular modeling; neuronal toxicity assays comparing clade B vs. clade C Tat","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assays plus mutagenesis plus functional toxicity; molecular mechanism partly based on modeling","pmids":["19020013"],"is_preprint":false},{"year":2008,"finding":"HIV-1 Tat localizes in nucleoli of cells and interacts with fibrillarin and U3 snoRNA (both required for pre-rRNA maturation), leading to impaired processing of ribosomal RNA precursors and decreased cytoplasmic ribosomes.","method":"Transgenic Drosophila expressing HIV-1 tat; immunolocalization showing co-localization with fibrillarin in nucleoli; ribosomal rRNA precursor processing assays; co-immunoprecipitation/interaction with fibrillarin and U3 snoRNA","journal":"BMC cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo localization with co-localization, interaction data, and functional rRNA processing assay; model organism system","pmids":["18559082"],"is_preprint":false},{"year":2010,"finding":"Tat is secreted by infected CD4+ T-cells through an unconventional pathway that does not involve the endoplasmic reticulum or known intracellular organelles. A Tat chimera with an N-glycosylation site was not glycosylated when expressed in cells but was glycosylated when introduced into purified microsomes, confirming ER-independent secretion. At 16°C, Tat secretion is inhibited and Tat accumulates at the plasma membrane, indicating secretion occurs at the plasma membrane level.","method":"N-glycosylation reporter chimera assay; pharmacological inhibitor studies; temperature-block experiments; subcellular fractionation","journal":"Cell biology international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches (glycosylation reporter, temperature block, pharmacological inhibitors), single lab","pmids":["19995346"],"is_preprint":false},{"year":2010,"finding":"Tat secretion by infected cells requires high-affinity binding to phosphatidylinositol(4,5)bisphosphate (PI(4,5)P2) concentrated in the inner leaflet of the plasma membrane, enabling Tat recruitment and membrane crossing. Following secretion, Tat binds various cell-surface receptors, is endocytosed, and low endosomal pH triggers a conformational change enabling membrane insertion. Translocation to the cytosol is assisted by Hsp90. The single tryptophan residue in Tat is important for membrane insertion.","method":"PI(4,5)P2 binding studies; conformational change assays at low pH; Hsp90 inhibition studies; tryptophan mutagenesis","journal":"Traffic (Copenhagen, Denmark)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic experiments but review-style compilation; some findings from referenced primary studies","pmids":["21951552"],"is_preprint":false},{"year":2016,"finding":"HIV-1 Tat protein is degraded by the 20S proteasome in an ubiquitin-independent manner (consistent with its intrinsically unfolded nature); curcumin activates the 20S proteasome and promotes dose- and time-dependent Tat degradation without affecting Tat mRNA levels. Proteasomal inhibitor MG132 blocks curcumin-induced Tat degradation. The properly folded HIV-1 Gag protein is not affected by curcumin.","method":"Cycloheximide chase assay; proteasome inhibitor (MG132) experiments; semi-quantitative RT-PCR; dose-response degradation assays in HEK-293T cells","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological and biochemical methods establishing proteasomal degradation; single lab","pmids":["27283735"],"is_preprint":false},{"year":2017,"finding":"The deubiquitinase USP7 stabilizes HIV-1 Tat protein through deubiquitination; inhibition of USP7 (by P5091 inhibitor or CRISPR-Cas9 deletion) leads to Tat protein degradation and reduced virus production. USP7 overexpression increases Tat-mediated HIV-1 production in a dose-dependent manner. HIV-1 infection up-regulates endogenous USP7 levels in human T-cells.","method":"USP7-specific inhibitor (P5091) and general DUB inhibitor (PR-619) treatment; CRISPR-Cas9 USP7 knockout; dose-dependent overexpression assays; western blot analysis; virus production assays in J1.1 latently infected T-cells","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition plus genetic knockout plus overexpression, single lab with multiple orthogonal methods","pmids":["28280111"],"is_preprint":false},{"year":2009,"finding":"Tat mRNA can be translated efficiently both in vitro and in cells, likely via an internal ribosome entry site (IRES) mechanism. Tat protein can strongly stimulate translation from its own cognate mRNA in a TAR-dependent fashion, providing a positive feedback loop to ensure sufficient Tat production early in infection.","method":"In vitro translation assays; monocistronic and dicistronic reporter RNA constructs with Tat 5'-UTR; cell-based translation assays; TAR deletion/mutation analysis","journal":"Retrovirology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro and cell-based reconstitution with defined RNA elements, single lab","pmids":["19671151"],"is_preprint":false},{"year":2000,"finding":"Thrombospondin-1 (TSP) binds directly to Tat protein with high affinity (Kd = 25 nM); TSP inhibits cell internalization and HIV-1 LTR trans-activating activity of extracellular Tat (ID50 = 10-30 nM), as well as Tat's mitogenic activity. TSP is ineffective once Tat has already bound to cell-surface heparan sulfate proteoglycans, and TSP prevents but does not disrupt Tat-heparin interaction in vitro.","method":"GST-Tat pulldown; Scatchard binding analysis; LTR trans-activation assays; cell internalization assays; heparin-Tat interaction competition assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding measurements with Scatchard analysis plus functional assays; single lab","pmids":["11023976"],"is_preprint":false},{"year":2016,"finding":"HIV-1 Tat expression in astrocytes induces lysosomal exocytosis, which is the mechanism of astrocyte-mediated Tat neurotoxicity. Tat-induced lysosomal exocytosis requires GFAP expression and is mediated through ER stress. Two-dimensional gel electrophoresis and mass spectrometry identified elevated lysosomal hydrolytic enzymes and plasma membrane-associated proteins in the conditioned medium of Tat-expressing astrocytes.","method":"2D gel electrophoresis and mass spectrometry; lysosomal exocytosis assays; GFAP knockout/knockdown; ER stress pathway analysis; conditioned medium neurotoxicity assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal approaches including proteomics, functional exocytosis assays, and genetic manipulation; single lab","pmids":["27609518"],"is_preprint":false},{"year":2020,"finding":"Two-pore channels (TPCs) in endolysosomes regulate Tat escape from endolysosomes into the cytosol and subsequent LTR transactivation; pharmacological blocking or knockdown of TPCs attenuates Tat endolysosome escape and LTR transactivation. Chelating endolysosomal or cytosolic calcium also attenuates Tat escape. TRPML1 knockdown has no effect, indicating specificity for TPCs.","method":"Pharmacological TPC inhibitors; TPC and TRPML1 siRNA knockdown; calcium chelation (rhodamine-dextran for endolysosomal Ca2+, BAPTA-AM for cytosolic Ca2+); LTR transactivation reporter assays; Tat endolysosome escape imaging assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological plus genetic (siRNA) approaches with appropriate controls (TRPML1 negative control); single lab","pmids":["31950548"],"is_preprint":false},{"year":2006,"finding":"Tat-derived peptides (but not full-length Tat protein itself) competitively and reversibly inhibit neprilysin, the major amyloid beta-peptide degrading enzyme in the brain. Both Tat peptides and Tat protein are slowly hydrolyzed by neprilysin, suggesting that proteolytic fragments accumulate and inhibit the enzyme.","method":"In vitro inhibition assays with recombinant neprilysin; kinetic analysis (competitive inhibition); comparison of Tat protein vs. Tat-derived peptides","journal":"Journal of neurovirology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic assay with kinetic characterization; single lab, distinguishes peptide fragments from full-length protein","pmids":["16877296"],"is_preprint":false}],"current_model":"HIV-1 Tat is a multifunctional viral protein that primarily activates transcriptional elongation from the HIV-1 LTR by binding to TAR RNA (specifically at its bulge region) and recruiting the P-TEFb complex (CDK9/cyclin T1), which hyperphosphorylates the RNA Pol II CTD; this activity is regulated by cycles of acetylation (by p300 at Lys50 and PCAF at Lys28) and deacetylation (by SIRT1), which control Tat's interaction with P-TEFb and TAR RNA respectively; Tat is also required for efficient reverse transcription, stimulates cotranscriptional mRNA capping via direct binding to the capping enzyme Mce1, is secreted unconventionally through the plasma membrane via PI(4,5)P2 binding and escapes endolysosomes via TPC-mediated calcium release, mimics beta-chemokines by binding CCR2 and CCR3 on monocytes, directly interacts with the NR1 subunit of NMDA receptors to cause neurotoxicity, enhances tubulin polymerization, impairs pre-rRNA processing through interaction with fibrillarin/U3 snoRNA in the nucleolus, and is stabilized by the deubiquitinase USP7 or degraded by the 20S proteasome in an ubiquitin-independent manner."},"narrative":{"mechanistic_narrative":"HIV-1 Tat is a multifunctional viral transactivator whose central function is to drive processive transcriptional elongation from the HIV-1 LTR by binding the nascent TAR RNA stem-loop [PMID:2247474, PMID:1903308] and converting paused polymerase complexes into elongation-competent ones [PMID:1658392, PMID:1752440]. Tat is organized into separable functional modules: an arginine-rich basic domain that binds the single-stranded bulge of TAR with nanomolar affinity [PMID:2247474, PMID:1903308], and a distinct activation domain that stimulates processivity even when tethered to RNA through a heterologous binding module [PMID:1658392, PMID:1752440]; the activation domain alone also supports transcription when Tat is recruited to promoter DNA, where the RNA-binding domain becomes dispensable [PMID:1752440]. Mechanistically, Tat recruits the P-TEFb kinase complex (CDK9/cyclin T1) to TAR, and cyclin T1 itself contributes TAR loop recognition to assemble a ternary Tat-cyclin T1-TAR complex that hyperphosphorylates the RNA Pol II CTD [PMID:10550206], with the cellular elongation cofactor Tat-SF1 and its associated factors SPT5 and the TFIIF subunit RAP30 required for full transactivation [PMID:8849451, PMID:9765201, PMID:10454543]. P-TEFb availability for Tat is constrained by HEXIM1, which represses Tat-dependent transcription via cyclin T1 and 7SK snRNA [PMID:15992410]. Tat activity is tuned by reversible acetylation: PCAF acetylates Lys28 to enhance P-TEFb binding while p300 acetylates Lys50 to release Tat from TAR during elongation [PMID:10545121], with the acetyl-Lys50 mark read by the PCAF bromodomain to drive synergistic activation [PMID:12032084], and SIRT1 deacetylates Tat to recycle it for further rounds of transcription [PMID:15719057]. Beyond elongation, Tat couples to co-transcriptional mRNA capping through direct binding of its C-terminus to the capping enzyme Mce1 [PMID:12408826] and is required in producer cells for efficient reverse transcription of progeny virions [PMID:9135139]. Tat acts extracellularly after unconventional secretion that bypasses the ER and occurs at the plasma membrane via PI(4,5)P2 binding [PMID:19995346, PMID:21951552], followed by endocytic uptake and TPC- and calcium-dependent escape from endolysosomes into the cytosol [PMID:31950548]; extracellular Tat mimics beta-chemokines by binding CCR2 and CCR3 to trigger monocyte calcium flux and migration [PMID:9789057], and contributes to neurotoxicity through direct engagement of the NMDA receptor NR1 subunit via its Cys30-Cys31 motif [PMID:19020013]. Tat protein levels are governed post-translationally by ubiquitin-independent 20S proteasomal degradation of the intrinsically unstructured protein [PMID:27283735] and by USP7-mediated deubiquitination that stabilizes Tat and supports virus production [PMID:28280111].","teleology":[{"year":1990,"claim":"Established the molecular basis of Tat target recognition by showing Tat binds a specific RNA element rather than acting through DNA alone, defining TAR as the transactivation-response RNA target.","evidence":"In vitro RNA-binding with bacterial Tat and synthetic TAR mutants, Scatchard analysis","pmids":["2247474","1903308"],"confidence":"High","gaps":["Does not explain why loop mutations abolish activity in vivo despite intact bulge binding in vitro","No cellular cofactor identified for TAR engagement"]},{"year":1991,"claim":"Resolved how Tat activates transcription by showing it enhances elongation/processivity rather than initiation, and that RNA-binding and activation functions are modular.","evidence":"Domain-swap tethering of Tat activation domains to R17/GAL4 RNA- and DNA-binding modules with LTR reporter assays","pmids":["1658392","1752440"],"confidence":"High","gaps":["The cellular elongation machinery recruited by the activation domain was not identified","Mechanism distinguishing RNA- vs DNA-tethered activation unclear"]},{"year":1995,"claim":"Provided the first structural framework for Tat, defining its domain architecture and intrinsic flexibility.","evidence":"2D NMR spectroscopy and molecular dynamics of recombinant Tat","pmids":["7723010"],"confidence":"High","gaps":["Flexible basic and cysteine-rich regions limit a defined fold","No structure of Tat bound to TAR or partners"]},{"year":1997,"claim":"Revealed a transcription-independent role by showing Tat is required in producer cells for efficient reverse transcription of progeny virions.","evidence":"tat-deleted virion production, producer- vs target-cell complementation, endogenous reverse transcription assays in PBMCs","pmids":["9135139"],"confidence":"High","gaps":["Molecular mechanism linking Tat to reverse transcription unresolved","Whether a virion-incorporated Tat species mediates the effect not defined"]},{"year":1998,"claim":"Identified the cellular cofactor network supporting Tat transactivation, placing Tat within the general elongation machinery.","evidence":"Functional complementation cloning of Tat-SF1, reciprocal co-IP with RAP30/hSPT5, immunodepletion/rescue and overexpression assays","pmids":["8849451","9765201","10454543"],"confidence":"High","gaps":["Direct vs indirect contacts between Tat and Tat-SF1/SPT5 not fully resolved","Stoichiometry within the elongation complex unknown"]},{"year":1999,"claim":"Defined the core kinase mechanism by showing Tat recruits P-TEFb (CDK9/cyclin T1) and that cyclin T1 supplies TAR loop recognition, reconciling in vitro binding with in vivo loop requirements.","evidence":"Dominant-negative CDK9, kinase inhibitors, ternary complex assays with cyclin T1 and TAR loop mutants","pmids":["10550206"],"confidence":"High","gaps":["Structural detail of the Tat-cyclin T1-TAR ternary complex not determined here","How CTD phosphorylation is coupled to downstream elongation factors unspecified"]},{"year":1999,"claim":"Established acetylation as a regulatory switch by mapping two HAT-specific sites with opposing functional consequences for P-TEFb binding and TAR release.","evidence":"In vitro acetylation, Lys28/Lys50 mutagenesis, co-IP and transactivation assays","pmids":["10545121"],"confidence":"High","gaps":["In vivo timing/ordering of the two acetylation events during a transcription cycle not resolved","Deacetylation step not yet identified at this stage"]},{"year":1999,"claim":"Extended Tat function to the extracellular space by showing it mimics beta-chemokines through CCR2/CCR3 engagement on monocytes.","evidence":"Ca2+ flux, migration, cross-desensitization, and competitive receptor-binding/displacement on CCR2/CCR3-transfected cells","pmids":["9789057"],"confidence":"High","gaps":["Structural basis of Tat-CCR2/CCR3 binding undefined","Physiological contribution to pathogenesis in vivo not established"]},{"year":1999,"claim":"Implicated Tat in neuronal apoptosis via GSK-3beta but clarified the interaction is indirect.","evidence":"GSK-3beta activity assays, co-precipitation, lithium rescue in rat cerebellar granule neurons","pmids":["10428053"],"confidence":"Medium","gaps":["The intermediary linking Tat to GSK-3beta activation is unknown","Co-precipitation without demonstrated direct enzymatic regulation"]},{"year":2000,"claim":"Identified thrombospondin-1 as a high-affinity extracellular regulator that neutralizes Tat uptake and transactivation before cell-surface engagement.","evidence":"GST-Tat pulldown, Scatchard analysis, internalization and LTR transactivation assays, heparin competition","pmids":["11023976"],"confidence":"Medium","gaps":["In vivo relevance of TSP-Tat antagonism not shown","Single-lab binding characterization"]},{"year":2002,"claim":"Connected acetylation to cofactor reading and to a second cotranscriptional step (capping), broadening Tat's elongation coupling.","evidence":"Structural analysis of acetyl-Lys50 Tat bound to PCAF bromodomain with mutagenesis; in vitro cotranscriptional capping assays defining the C-terminal Tat-Mce1 interaction","pmids":["12032084","12408826"],"confidence":"High","gaps":["Capping data are single-lab in vitro reconstitution","How bromodomain reading is temporally integrated with TAR release unresolved"]},{"year":2005,"claim":"Completed the acetylation cycle by identifying SIRT1 as the deacetylase that recycles Tat for repeated transcription rounds, and added microtubule, mitochondrial, and LIS1 connections.","evidence":"In vitro deacetylation, co-IP, SIRT1-null MEF rescue; tubulin polymerization and mitochondrial cytochrome c assays; biochemical fractionation/co-IP/Y2H for LIS1","pmids":["15719057","15691386","15698475"],"confidence":"Medium","gaps":["Functional consequence of Tat-LIS1 and tubulin effects for infection vs neurotoxicity unclear","Tubulin/mitochondrial findings are single-lab in vitro"]},{"year":2005,"claim":"Defined a negative regulatory arm of P-TEFb availability constraining Tat function.","evidence":"HEXIM1 domain-mutant repression assays and GAL4-CycT1 artificial recruitment with LTR reporters","pmids":["15992410"],"confidence":"Medium","gaps":["Dynamics of HEXIM1/7SK release to license Tat not resolved here","Single-lab functional assays"]},{"year":2008,"claim":"Established direct receptor- and organelle-level mechanisms of Tat neurotoxicity and effects on ribosome biogenesis.","evidence":"Direct Tat-NR1 binding with Cys31Ser mutagenesis and clade comparison; transgenic Drosophila nucleolar localization with fibrillarin/U3 snoRNA interaction and rRNA processing assays","pmids":["19020013","18559082"],"confidence":"Medium","gaps":["NMDA receptor mechanism partly modeling-based","rRNA processing effect shown in a model organism system"]},{"year":2010,"claim":"Defined the unconventional secretion route, showing Tat exits at the plasma membrane via PI(4,5)P2 binding independent of the ER.","evidence":"N-glycosylation reporter chimera, temperature-block, fractionation; PI(4,5)P2 binding, low-pH conformational change and Hsp90/tryptophan studies","pmids":["19995346","21951552"],"confidence":"Medium","gaps":["Molecular machinery driving membrane crossing not fully reconstituted","Some mechanistic claims compiled review-style"]},{"year":2016,"claim":"Defined post-translational control of Tat abundance and a lysosome-based neurotoxic mechanism.","evidence":"Cycloheximide chase, MG132 and curcumin-induced 20S degradation assays; GFAP-dependent lysosomal exocytosis with proteomics and ER stress analysis in astrocytes","pmids":["27283735","27609518"],"confidence":"Medium","gaps":["Endogenous physiological trigger of 20S degradation unspecified","Astrocyte exocytosis pathway is single-lab"]},{"year":2017,"claim":"Identified USP7 as a deubiquitinase that stabilizes Tat and promotes virus production, complementing ubiquitin-independent turnover.","evidence":"P5091 inhibition, CRISPR USP7 knockout, dose-dependent overexpression, and virus production assays in latently infected T-cells","pmids":["28280111"],"confidence":"Medium","gaps":["The ubiquitin ligase opposing USP7 not identified","Reconciliation with ubiquitin-independent 20S degradation unclear"]},{"year":2020,"claim":"Resolved how extracellular Tat reaches the cytosol by implicating two-pore channels and endolysosomal calcium in endolysosome escape.","evidence":"TPC pharmacological inhibitors and siRNA, calcium chelation, TRPML1 negative control, and LTR transactivation/escape imaging assays","pmids":["31950548"],"confidence":"Medium","gaps":["Direct molecular interaction between Tat and TPC machinery not established","Single-lab study"]},{"year":null,"claim":"It remains unresolved how the many Tat activities — elongation, capping, reverse transcription, secretion/uptake, and the multiple neurotoxic and immunomodulatory extracellular functions — are temporally and spatially coordinated within an infection, and how the opposing degradation (20S) and stabilization (USP7) pathways set Tat levels in vivo.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated structural model of the Tat-P-TEFb-TAR-cofactor elongation complex","The ubiquitin ligase and physiological signals governing Tat turnover are unidentified","In vivo contribution of extracellular Tat functions to pathogenesis not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,4]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,2,4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,5,10]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[7]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[12,13]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[20]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[18]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,6]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[19,20]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[20,26]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[7,19]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,4]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[10,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[15,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7]}],"complexes":["P-TEFb (CDK9/cyclin T1)"],"partners":["CCNT1","CDK9","TATSF1","SUPT5H","EP300","KAT2B","SIRT1","USP7"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P17735","full_name":"Tyrosine aminotransferase","aliases":["L-tyrosine:2-oxoglutarate aminotransferase"],"length_aa":454,"mass_kda":50.4,"function":"Transaminase involved in tyrosine breakdown. Converts tyrosine to p-hydroxyphenylpyruvate. Can catalyze the reverse reaction, using glutamic acid, with 2-oxoglutarate as cosubstrate (in vitro). Has much lower affinity and transaminase activity towards phenylalanine","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P17735/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TAT","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TAT","total_profiled":1310},"omim":[{"mim_id":"621074","title":"MITOTIC DEACETYLASE-ASSOCIATED SANT DOMAIN PROTEIN; MIDEAS","url":"https://www.omim.org/entry/621074"},{"mim_id":"619772","title":"PROTEASOMAL ATPase-ASSOCIATED FACTOR 1; PAAF1","url":"https://www.omim.org/entry/619772"},{"mim_id":"619364","title":"TatD DNase DOMAIN-CONTAINING PROTEIN 1; TATDN1","url":"https://www.omim.org/entry/619364"},{"mim_id":"619214","title":"ZINC FINGER PROTEIN 639; ZNF639","url":"https://www.omim.org/entry/619214"},{"mim_id":"617485","title":"WD REPEAT- AND FYVE DOMAIN-CONTAINING PROTEIN 3; WDFY3","url":"https://www.omim.org/entry/617485"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":1188.4}],"url":"https://www.proteinatlas.org/search/TAT"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P17735","domains":[{"cath_id":"3.90.1150.10","chopping":"48-84_335-440","consensus_level":"medium","plddt":96.05,"start":48,"end":440},{"cath_id":"3.40.640.10","chopping":"91-332","consensus_level":"medium","plddt":98.3824,"start":91,"end":332}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P17735","model_url":"https://alphafold.ebi.ac.uk/files/AF-P17735-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P17735-F1-predicted_aligned_error_v6.png","plddt_mean":91.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TAT","jax_strain_url":"https://www.jax.org/strain/search?query=TAT"},"sequence":{"accession":"P17735","fasta_url":"https://rest.uniprot.org/uniprotkb/P17735.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P17735/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P17735"}},"corpus_meta":[{"pmid":"8290579","id":"PMC_8290579","title":"Tat-mediated delivery of heterologous proteins into cells.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8290579","citation_count":1017,"is_preprint":false},{"pmid":"10652088","id":"PMC_10652088","title":"The Tat protein export pathway.","date":"2000","source":"Molecular microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/10652088","citation_count":452,"is_preprint":false},{"pmid":"22683878","id":"PMC_22683878","title":"The twin-arginine translocation (Tat) protein export pathway.","date":"2012","source":"Nature reviews. Microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/22683878","citation_count":390,"is_preprint":false},{"pmid":"10550206","id":"PMC_10550206","title":"Tackling Tat.","date":"1999","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10550206","citation_count":365,"is_preprint":false},{"pmid":"10545121","id":"PMC_10545121","title":"HIV-1 tat transcriptional activity is regulated by acetylation.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10545121","citation_count":361,"is_preprint":false},{"pmid":"11403574","id":"PMC_11403574","title":"TAT-mediated protein transduction into mammalian cells.","date":"2001","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/11403574","citation_count":310,"is_preprint":false},{"pmid":"17913584","id":"PMC_17913584","title":"TAT transduction: the molecular mechanism and therapeutic prospects.","date":"2007","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17913584","citation_count":284,"is_preprint":false},{"pmid":"15719057","id":"PMC_15719057","title":"SIRT1 regulates HIV transcription via Tat deacetylation.","date":"2005","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/15719057","citation_count":282,"is_preprint":false},{"pmid":"9789057","id":"PMC_9789057","title":"HIV-1 Tat protein mimicry of chemokines.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9789057","citation_count":228,"is_preprint":false},{"pmid":"1752440","id":"PMC_1752440","title":"The HIV-1 Tat protein activates transcription from an upstream DNA-binding site: implications for Tat function.","date":"1991","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1752440","citation_count":226,"is_preprint":false},{"pmid":"2247474","id":"PMC_2247474","title":"Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2247474","citation_count":207,"is_preprint":false},{"pmid":"21951552","id":"PMC_21951552","title":"The ins and outs of HIV-1 Tat.","date":"2011","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/21951552","citation_count":195,"is_preprint":false},{"pmid":"12678851","id":"PMC_12678851","title":"TAT peptide internalization: seeking the mechanism of entry.","date":"2003","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/12678851","citation_count":194,"is_preprint":false},{"pmid":"14560665","id":"PMC_14560665","title":"The Tat protein translocation pathway and its role in microbial physiology.","date":"2003","source":"Advances in microbial physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14560665","citation_count":192,"is_preprint":false},{"pmid":"15802249","id":"PMC_15802249","title":"Protein targeting by the bacterial twin-arginine translocation (Tat) pathway.","date":"2005","source":"Current opinion in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/15802249","citation_count":175,"is_preprint":false},{"pmid":"7723010","id":"PMC_7723010","title":"Structural studies of HIV-1 Tat protein.","date":"1995","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7723010","citation_count":165,"is_preprint":false},{"pmid":"8849451","id":"PMC_8849451","title":"Tat-SF1: cofactor for stimulation of transcriptional elongation by HIV-1 Tat.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8849451","citation_count":144,"is_preprint":false},{"pmid":"10428053","id":"PMC_10428053","title":"HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity.","date":"1999","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10428053","citation_count":142,"is_preprint":false},{"pmid":"12029389","id":"PMC_12029389","title":"Sequence and phylogenetic analyses of the twin-arginine targeting (Tat) protein export system.","date":"2002","source":"Archives of microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/12029389","citation_count":141,"is_preprint":false},{"pmid":"16280076","id":"PMC_16280076","title":"Tat gets the \"green\" light on transcription initiation.","date":"2005","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/16280076","citation_count":132,"is_preprint":false},{"pmid":"9135139","id":"PMC_9135139","title":"Tat is required for efficient HIV-1 reverse transcription.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9135139","citation_count":132,"is_preprint":false},{"pmid":"19526283","id":"PMC_19526283","title":"Role of Tat protein in HIV neuropathogenesis.","date":"2009","source":"Neurotoxicity research","url":"https://pubmed.ncbi.nlm.nih.gov/19526283","citation_count":124,"is_preprint":false},{"pmid":"12408826","id":"PMC_12408826","title":"Tat stimulates cotranscriptional capping of HIV mRNA.","date":"2002","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12408826","citation_count":119,"is_preprint":false},{"pmid":"31789815","id":"PMC_31789815","title":"Presence of Tat and transactivation response element in spinal fluid despite antiretroviral therapy.","date":"2019","source":"AIDS (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31789815","citation_count":117,"is_preprint":false},{"pmid":"7693046","id":"PMC_7693046","title":"Exogenous tat protein activates human endothelial cells.","date":"1993","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7693046","citation_count":115,"is_preprint":false},{"pmid":"12032084","id":"PMC_12032084","title":"Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12032084","citation_count":115,"is_preprint":false},{"pmid":"15546663","id":"PMC_15546663","title":"Tat-dependent protein targeting in prokaryotes and chloroplasts.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15546663","citation_count":114,"is_preprint":false},{"pmid":"19020013","id":"PMC_19020013","title":"NMDA receptor activation by HIV-Tat protein is clade dependent.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19020013","citation_count":111,"is_preprint":false},{"pmid":"12163436","id":"PMC_12163436","title":"TAT protein transduction into isolated perfused hearts: TAT-apoptosis repressor with caspase recruitment domain is cardioprotective.","date":"2002","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12163436","citation_count":109,"is_preprint":false},{"pmid":"14595670","id":"PMC_14595670","title":"Intracellular cargo delivery using tat peptide and derivatives.","date":"2004","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/14595670","citation_count":107,"is_preprint":false},{"pmid":"10448148","id":"PMC_10448148","title":"HIV-1 Tat: coping with negative elongation factors.","date":"1999","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10448148","citation_count":96,"is_preprint":false},{"pmid":"15722166","id":"PMC_15722166","title":"Transcellular protein transduction using the Tat protein of HIV-1.","date":"2005","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15722166","citation_count":90,"is_preprint":false},{"pmid":"16092529","id":"PMC_16092529","title":"The Tat pathway in bacteria and chloroplasts (review).","date":"2005","source":"Molecular membrane biology","url":"https://pubmed.ncbi.nlm.nih.gov/16092529","citation_count":88,"is_preprint":false},{"pmid":"16622015","id":"PMC_16622015","title":"TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16622015","citation_count":88,"is_preprint":false},{"pmid":"1638124","id":"PMC_1638124","title":"Activation of HIV transcription by Tat.","date":"1992","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/1638124","citation_count":87,"is_preprint":false},{"pmid":"27283735","id":"PMC_27283735","title":"Curcumin inhibits HIV-1 by promoting Tat protein degradation.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27283735","citation_count":87,"is_preprint":false},{"pmid":"12678852","id":"PMC_12678852","title":"TAT-liposomes: a novel intracellular drug carrier.","date":"2003","source":"Current protein & peptide science","url":"https://pubmed.ncbi.nlm.nih.gov/12678852","citation_count":83,"is_preprint":false},{"pmid":"32158701","id":"PMC_32158701","title":"HIV-1 Tat: Role in Bystander Toxicity.","date":"2020","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/32158701","citation_count":79,"is_preprint":false},{"pmid":"8352964","id":"PMC_8352964","title":"Tat and the HIV-1 promoter.","date":"1993","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8352964","citation_count":77,"is_preprint":false},{"pmid":"11716691","id":"PMC_11716691","title":"Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo.","date":"2001","source":"Bioconjugate chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11716691","citation_count":77,"is_preprint":false},{"pmid":"19462331","id":"PMC_19462331","title":"Morphine enhances Tat-induced activation in murine microglia.","date":"2009","source":"Journal of neurovirology","url":"https://pubmed.ncbi.nlm.nih.gov/19462331","citation_count":77,"is_preprint":false},{"pmid":"15653153","id":"PMC_15653153","title":"Influence of TAT-peptide polymerization on properties and transfection activity of TAT/DNA polyplexes.","date":"2005","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/15653153","citation_count":77,"is_preprint":false},{"pmid":"24268201","id":"PMC_24268201","title":"Long-term efficient gene delivery using polyethylenimine with modified Tat peptide.","date":"2013","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/24268201","citation_count":74,"is_preprint":false},{"pmid":"19478831","id":"PMC_19478831","title":"Functional substitution by TAT-utrophin in dystrophin-deficient mice.","date":"2009","source":"PLoS medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19478831","citation_count":73,"is_preprint":false},{"pmid":"24140208","id":"PMC_24140208","title":"The Tat system of Gram-positive bacteria.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24140208","citation_count":70,"is_preprint":false},{"pmid":"31401776","id":"PMC_31401776","title":"Transport of Folded Proteins by the Tat System.","date":"2019","source":"The protein journal","url":"https://pubmed.ncbi.nlm.nih.gov/31401776","citation_count":70,"is_preprint":false},{"pmid":"17481667","id":"PMC_17481667","title":"Tit-for-tat or win-stay, lose-shift?","date":"2007","source":"Journal of theoretical biology","url":"https://pubmed.ncbi.nlm.nih.gov/17481667","citation_count":70,"is_preprint":false},{"pmid":"1658392","id":"PMC_1658392","title":"A minimal lentivirus Tat.","date":"1991","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/1658392","citation_count":69,"is_preprint":false},{"pmid":"10535742","id":"PMC_10535742","title":"HIV-1-trans-activating (Tat) protein: both a target and a tool in therapeutic approaches.","date":"1999","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10535742","citation_count":67,"is_preprint":false},{"pmid":"19995346","id":"PMC_19995346","title":"HIV-1 Tat is unconventionally secreted through the plasma membrane.","date":"2010","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/19995346","citation_count":63,"is_preprint":false},{"pmid":"28457951","id":"PMC_28457951","title":"HIV, Tat and dopamine transmission.","date":"2017","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28457951","citation_count":62,"is_preprint":false},{"pmid":"9765201","id":"PMC_9765201","title":"The HIV-1 Tat cellular coactivator Tat-SF1 is a general transcription elongation factor.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9765201","citation_count":61,"is_preprint":false},{"pmid":"10089212","id":"PMC_10089212","title":"The tat protein of HIV-1 induces galectin-3 expression.","date":"1999","source":"Glycobiology","url":"https://pubmed.ncbi.nlm.nih.gov/10089212","citation_count":60,"is_preprint":false},{"pmid":"25975269","id":"PMC_25975269","title":"Mechanistic Aspects of Folded Protein Transport by the Twin Arginine Translocase (Tat).","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25975269","citation_count":59,"is_preprint":false},{"pmid":"16156649","id":"PMC_16156649","title":"TAR RNA recognition by a cyclic peptidomimetic of Tat protein.","date":"2005","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16156649","citation_count":55,"is_preprint":false},{"pmid":"16146763","id":"PMC_16146763","title":"The multiple functions of HIV-1 Tat: proliferation versus apoptosis.","date":"2006","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/16146763","citation_count":55,"is_preprint":false},{"pmid":"19074606","id":"PMC_19074606","title":"TatABC overexpression improves Corynebacterium glutamicum Tat-dependent protein secretion.","date":"2008","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/19074606","citation_count":54,"is_preprint":false},{"pmid":"27914200","id":"PMC_27914200","title":"Assembling the Tat protein translocase.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27914200","citation_count":51,"is_preprint":false},{"pmid":"15691386","id":"PMC_15691386","title":"HIV-1 Tat protein enhances microtubule polymerization.","date":"2005","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/15691386","citation_count":51,"is_preprint":false},{"pmid":"10454543","id":"PMC_10454543","title":"Tat-SF1 protein associates with RAP30 and human SPT5 proteins.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10454543","citation_count":49,"is_preprint":false},{"pmid":"16046164","id":"PMC_16046164","title":"Decoding Tat: the biology of HIV Tat posttranslational modifications.","date":"2005","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/16046164","citation_count":49,"is_preprint":false},{"pmid":"24583120","id":"PMC_24583120","title":"Protein transport by the bacterial Tat pathway.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24583120","citation_count":48,"is_preprint":false},{"pmid":"17206479","id":"PMC_17206479","title":"TAT-Bim induces extensive apoptosis in cancer cells.","date":"2007","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17206479","citation_count":48,"is_preprint":false},{"pmid":"28495611","id":"PMC_28495611","title":"HIV-1 TAT protein enhances sensitization to methamphetamine by affecting dopaminergic function.","date":"2017","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/28495611","citation_count":47,"is_preprint":false},{"pmid":"23875777","id":"PMC_23875777","title":"Synaptodendritic recovery following HIV Tat exposure: neurorestoration by phytoestrogens.","date":"2013","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23875777","citation_count":45,"is_preprint":false},{"pmid":"16877296","id":"PMC_16877296","title":"Tat peptides inhibit neprilysin.","date":"2006","source":"Journal of neurovirology","url":"https://pubmed.ncbi.nlm.nih.gov/16877296","citation_count":44,"is_preprint":false},{"pmid":"28280111","id":"PMC_28280111","title":"USP7 deubiquitinase controls HIV-1 production by stabilizing Tat protein.","date":"2017","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/28280111","citation_count":44,"is_preprint":false},{"pmid":"20339348","id":"PMC_20339348","title":"Multiple precursor proteins bind individual Tat receptor complexes and are collectively transported.","date":"2010","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/20339348","citation_count":43,"is_preprint":false},{"pmid":"26405806","id":"PMC_26405806","title":"TAT Modification of Alpha-Helical Anticancer Peptides to Improve Specificity and Efficacy.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26405806","citation_count":43,"is_preprint":false},{"pmid":"19601640","id":"PMC_19601640","title":"TAT peptide and its conjugates: proteolytic stability.","date":"2009","source":"Bioconjugate chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19601640","citation_count":43,"is_preprint":false},{"pmid":"21204735","id":"PMC_21204735","title":"Tits and bits of HIV Tat protein.","date":"2011","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21204735","citation_count":40,"is_preprint":false},{"pmid":"18559082","id":"PMC_18559082","title":"The HIV Tat protein affects processing of ribosomal RNA precursor.","date":"2008","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18559082","citation_count":40,"is_preprint":false},{"pmid":"19671151","id":"PMC_19671151","title":"Mechanism of HIV-1 Tat RNA translation and its activation by the Tat protein.","date":"2009","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/19671151","citation_count":39,"is_preprint":false},{"pmid":"20414733","id":"PMC_20414733","title":"Activation of Egr-1 expression in astrocytes by HIV-1 Tat: new insights into astrocyte-mediated Tat neurotoxicity.","date":"2010","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20414733","citation_count":39,"is_preprint":false},{"pmid":"23454193","id":"PMC_23454193","title":"Increased excitability in tat-transgenic mice: role of tat in HIV-related neurological disorders.","date":"2013","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/23454193","citation_count":39,"is_preprint":false},{"pmid":"12584340","id":"PMC_12584340","title":"Tat-neutralizing antibodies in vaccinated macaques.","date":"2003","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/12584340","citation_count":38,"is_preprint":false},{"pmid":"27609518","id":"PMC_27609518","title":"HIV-1 Tat Promotes Lysosomal Exocytosis in Astrocytes and Contributes to Astrocyte-mediated Tat Neurotoxicity.","date":"2016","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27609518","citation_count":38,"is_preprint":false},{"pmid":"1903308","id":"PMC_1903308","title":"RNA binding by the tat and rev proteins of HIV-1.","date":"1991","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/1903308","citation_count":37,"is_preprint":false},{"pmid":"20060860","id":"PMC_20060860","title":"Improved Tat-mediated plasmid DNA transfer by fusion to LK15 peptide.","date":"2010","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/20060860","citation_count":37,"is_preprint":false},{"pmid":"31950548","id":"PMC_31950548","title":"Two-pore channels regulate Tat endolysosome escape and Tat-mediated HIV-1 LTR transactivation.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31950548","citation_count":36,"is_preprint":false},{"pmid":"25339738","id":"PMC_25339738","title":"Effects of HIV-1 Tat on enteric neuropathogenesis.","date":"2014","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25339738","citation_count":36,"is_preprint":false},{"pmid":"9651670","id":"PMC_9651670","title":"Transcriptional control: Tat cofactors and transcriptional elongation.","date":"1998","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9651670","citation_count":35,"is_preprint":false},{"pmid":"16535863","id":"PMC_16535863","title":"Discoveries of Tat-TAR interaction inhibitors for HIV-1.","date":"2005","source":"Current drug targets. Infectious disorders","url":"https://pubmed.ncbi.nlm.nih.gov/16535863","citation_count":34,"is_preprint":false},{"pmid":"29534516","id":"PMC_29534516","title":"TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29534516","citation_count":34,"is_preprint":false},{"pmid":"16472655","id":"PMC_16472655","title":"Purification of TAT-C3 exoenzyme.","date":"2006","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/16472655","citation_count":34,"is_preprint":false},{"pmid":"15992410","id":"PMC_15992410","title":"Inhibition of Tat activity by the HEXIM1 protein.","date":"2005","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/15992410","citation_count":34,"is_preprint":false},{"pmid":"25851770","id":"PMC_25851770","title":"Delayed Administration of Tat-HA-NR2B9c Promotes Recovery After Stroke in Rats.","date":"2015","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/25851770","citation_count":33,"is_preprint":false},{"pmid":"10980447","id":"PMC_10980447","title":"Blocking HIV replication by targeting Tat protein.","date":"2000","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/10980447","citation_count":30,"is_preprint":false},{"pmid":"9570510","id":"PMC_9570510","title":"Tat, Tat-associated kinase, and transcription.","date":"1998","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/9570510","citation_count":29,"is_preprint":false},{"pmid":"15698475","id":"PMC_15698475","title":"HIV-1 Tat interacts with LIS1 protein.","date":"2005","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/15698475","citation_count":29,"is_preprint":false},{"pmid":"15203910","id":"PMC_15203910","title":"Factors controlling the efficiency of Tat-mediated plasmid DNA transfer.","date":"2004","source":"Journal of drug targeting","url":"https://pubmed.ncbi.nlm.nih.gov/15203910","citation_count":28,"is_preprint":false},{"pmid":"26443788","id":"PMC_26443788","title":"The Tat Protein Export Pathway.","date":"2010","source":"EcoSal Plus","url":"https://pubmed.ncbi.nlm.nih.gov/26443788","citation_count":27,"is_preprint":false},{"pmid":"15651064","id":"PMC_15651064","title":"Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer.","date":"2005","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15651064","citation_count":27,"is_preprint":false},{"pmid":"24696163","id":"PMC_24696163","title":"PACAP27 is protective against tat-induced neurotoxicity.","date":"2014","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/24696163","citation_count":27,"is_preprint":false},{"pmid":"19151138","id":"PMC_19151138","title":"Differential Interactions between Tat-specific redox enzyme peptides and their chaperones.","date":"2009","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/19151138","citation_count":27,"is_preprint":false},{"pmid":"16614736","id":"PMC_16614736","title":"TAT-GDNF in neurodegeneration and ischemic stroke.","date":"2005","source":"CNS drug reviews","url":"https://pubmed.ncbi.nlm.nih.gov/16614736","citation_count":26,"is_preprint":false},{"pmid":"8552302","id":"PMC_8552302","title":"Neurotoxic mechanisms of transactivating protein Tat of Maedi-Visna virus.","date":"1995","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/8552302","citation_count":26,"is_preprint":false},{"pmid":"11023976","id":"PMC_11023976","title":"Thrombospondin-1/HIV-1 tat protein interaction: modulation of the biological activity of extracellular Tat.","date":"2000","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/11023976","citation_count":25,"is_preprint":false},{"pmid":"32084398","id":"PMC_32084398","title":"The Plant Mitochondrial TAT Pathway Is Essential for Complex III Biogenesis.","date":"2020","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/32084398","citation_count":24,"is_preprint":false},{"pmid":"12445831","id":"PMC_12445831","title":"Transduction of TAT fusion proteins into osteoclasts and osteoblasts.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12445831","citation_count":24,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":83232,"output_tokens":8395,"usd":0.309877,"retried_sync":true,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17134,"output_tokens":5871,"usd":0.116223,"stage2_stop_reason":"end_turn"},"total_usd":0.4261,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking at the corpus, I need to distinguish between:\n1. HIV-1 Tat protein (the viral transactivator) - clearly the main subject\n2. Bacterial/chloroplast Tat (twin-arginine translocation) pathway - a completely different system\n3. TAT as \"tumor-associated trypsinogens\" (paper 93) - different gene entirely\n4. Various TAT-fusion protein delivery papers - these use HIV Tat as a tool but don't establish new mechanisms about Tat itself\n5. Game theory \"tit-for-tat\" paper (47) - irrelevant\n\nI'll focus on papers that establish direct mechanistic findings about HIV-1 Tat protein function.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"HIV-1 Tat protein binds selectively to TAR RNA in vitro with specificity mapping to the single-stranded 'bulge' region of the TAR stem-loop; the basic region of Tat is sufficient for TAR RNA binding, forming a one-to-one complex with Kd ~12 nM. Mutations in the bulge reduced affinity 6-10 fold, while loop mutations did not affect Tat binding.\",\n      \"method\": \"In vitro RNA-binding assay with bacterially expressed Tat protein and synthetic TAR RNA; competition assays with TAR mutants; Scatchard analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, replicated across multiple labs (PMID:2247474 and PMID:1903308)\",\n      \"pmids\": [\"2247474\", \"1903308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Tat activates HIV transcription primarily by enhancing transcriptional elongation rather than initiation; a minimal Tat activation domain of ~47 amino acids (HIV-1) or 15 amino acids (EIAV) is sufficient to stimulate processivity of transcription complexes when tethered to nascent RNA. The RNA-binding domain (~10 aa) and activation domain are separable functional modules.\",\n      \"method\": \"Protein fusion experiments tethering Tat activation domains to heterologous RNA-binding domains (bacteriophage R17 coat protein); transcriptional assays on LTR reporters\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution using domain-swap and tethering experiments, replicated across multiple studies (PMID:1658392, PMID:1752440)\",\n      \"pmids\": [\"1658392\", \"1752440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Tat can function when bound to upstream promoter DNA rather than TAR RNA; the activation domain required for RNA-bound Tat is also required for DNA-bound Tat, but the arginine-rich RNA-binding domain is dispensable for DNA-bound Tat function. Tat activity requires cooperation with promoter-bound cellular transcription factors in both contexts.\",\n      \"method\": \"Protein fusion experiments with GAL4 DNA-binding domain; transcriptional reporter assays; domain mutagenesis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with domain mutagenesis, single lab\",\n      \"pmids\": [\"1752440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Tat-SF1 is a cellular cofactor required for Tat transactivation; it associates with a cellular kinase and is a substrate of that kinase. Tat-SF1 contains two RNA recognition motifs and an acidic C-terminal half. Co-transfection of Tat-SF1 cDNA specifically modulates Tat activation, and Tat-SF1 functions as a general transcription elongation factor.\",\n      \"method\": \"cDNA isolation by functional complementation; co-transfection transcriptional assays; protein-affinity chromatography; immunodepletion and complementation with recombinant proteins\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including functional complementation, immunodepletion, and affinity chromatography across two studies (PMID:8849451, PMID:9765201)\",\n      \"pmids\": [\"8849451\", \"9765201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Tat stimulates transcriptional elongation by recruiting the TAK (Tat-associated kinase) complex, which contains CDK9 and cyclin T1 (P-TEFb), to the transcription machinery via TAR RNA. This results in hyperphosphorylation of the RNA polymerase II CTD. Cyclin T1 participates in TAR RNA recognition and enables Tat to form a ternary complex with TAR RNA only when a functional loop sequence is present, explaining why loop mutations abolish Tat activity in vivo but not Tat-TAR binding in vitro.\",\n      \"method\": \"Dominant-negative CDK9 kinase inhibition assays; kinase inhibitor studies; ternary complex formation assays with cyclin T1 and TAR RNA loop mutants\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (dominant-negative mutants, kinase inhibitors, RNA-protein complex assays), replicated across labs\",\n      \"pmids\": [\"10550206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HIV-1 Tat is directly acetylated at two distinct sites by two different HATs: p300 acetylates Lys50 in the TAR RNA binding domain, and PCAF acetylates Lys28 in the activation domain. Acetylation at Lys28 by PCAF enhances Tat binding to CDK9/P-TEFb, while acetylation at Lys50 by p300 promotes dissociation of Tat from TAR RNA during transcription elongation.\",\n      \"method\": \"In vitro acetylation assays; site-directed mutagenesis of Lys28 and Lys50; co-immunoprecipitation; transcriptional activation assays; trichostatin A synergy experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro acetylation with mutagenesis plus functional transcription assays and co-IP, multiple orthogonal methods in one study\",\n      \"pmids\": [\"10545121\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Tat-SF1 associates with RAP30 (a subunit of TFIIF) and human SPT5 (hSPT5) in nuclear extracts; immunodepletion of Tat-SF1 abolishes Tat activation which is rescued by recombinant Tat-SF1; overexpression of Tat-SF1 and hSPT5 specifically stimulates Tat transcriptional activity in vivo. RAP74 subunit of TFIIF is not co-immunoprecipitated with Tat-SF1.\",\n      \"method\": \"Co-immunoprecipitation from nuclear extracts; immunodepletion with complementation; overexpression assays; transcriptional activation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, immunodepletion/rescue, and functional overexpression across multiple orthogonal methods\",\n      \"pmids\": [\"10454543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HIV-1 Tat protein mimics beta-chemokines: it induces rapid transient Ca2+ influx in monocytes/macrophages via pertussis toxin-sensitive receptors, causes monocyte migration, and cross-desensitizes with MCP-1, MCP-3, and eotaxin. Tat displaces beta-chemokines from receptors CCR2 and CCR3 (but not CCR1, CCR4, CCR5), and a Tat peptide (CysL24-51) directly binds cells transfected with CCR2 and CCR3.\",\n      \"method\": \"Ca2+ influx assays; monocyte migration assays; cross-desensitization studies; competitive receptor binding displacement; direct binding to CCR2/CCR3-transfected cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Ca2+ flux, migration, receptor binding, cross-desensitization) in a single rigorous study\",\n      \"pmids\": [\"9789057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Tat-induced neuronal apoptosis involves activation of glycogen synthase kinase-3beta (GSK-3beta); Tat co-precipitates with GSK-3beta but direct addition of Tat to purified GSK-3beta has no effect on enzyme activity, indicating Tat's effects on GSK-3beta are indirect. PAF receptor activation also activates GSK-3beta. Lithium (GSK-3beta inhibitor) enhances neuronal survival after Tat exposure.\",\n      \"method\": \"GSK-3beta kinase activity assays; co-precipitation; lithium treatment rescue experiments; PAF receptor activation studies in rat cerebellar granule neurons\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-precipitation plus enzymatic activity assays plus pharmacological rescue, single lab\",\n      \"pmids\": [\"10428053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Transcriptional synergy between Tat and PCAF requires acetylation of Lys50 of Tat and the PCAF bromodomain. Structural analysis defined critical interaction residues: Y47 and R53 in Tat, and V763, Y802, Y809 in PCAF bromodomain. Mutation of these residues inhibits Tat-PCAF interaction in vitro and in vivo and abrogates HIV promoter synergistic activation.\",\n      \"method\": \"In vitro and in vivo binding assays; structural analysis of acetylated Tat peptide bound to PCAF bromodomain; site-directed mutagenesis; HIV promoter transactivation assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural data combined with mutagenesis and functional transcription assays, multiple orthogonal methods\",\n      \"pmids\": [\"12032084\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Tat stimulates cotranscriptional capping of HIV mRNA; this stimulation requires the C-terminal segment of Tat that mediates direct binding to the capping enzyme Mce1. Both Mce1 and the cap methyltransferase Hcm1 travel with Pol II during elongation and require CTD phosphorylation for stable binding to template-engaged Pol II.\",\n      \"method\": \"In vitro transcription/capping assays with template-engaged Pol II; domain deletion studies identifying C-terminal Tat-Mce1 binding region; cotranscriptional capping efficiency measurements\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with defined domain requirements, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"12408826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Tat is deacetylated by SIRT1, a NAD-dependent class III deacetylase, in vitro and in vivo; Tat and SIRT1 co-immunoprecipitate and synergistically activate the HIV promoter. Knockdown of SIRT1 or treatment with SIRT1 inhibitors inhibit Tat-mediated transactivation. Tat transactivation is defective in SIRT1-null MEFs and rescued by SIRT1 re-expression. SIRT1 recycles Tat to its unacetylated form to enable repeated rounds of transcription.\",\n      \"method\": \"In vitro deacetylation assays; co-immunoprecipitation; siRNA knockdown; SIRT1-null MEF rescue experiments; HIV LTR transactivation assays\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro enzymatic assay plus co-IP plus genetic null rescue, multiple orthogonal methods in single study\",\n      \"pmids\": [\"15719057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Tat protein directly enhances tubulin polymerization; residues 38-72 of Tat are responsible for this activity. Tat can also directly trigger the mitochondrial apoptosis pathway, as evidenced by release of cytochrome c from isolated mitochondria in vitro.\",\n      \"method\": \"Tubulin polymerization assays with recombinant Tat variants and truncation peptides; cytochrome c release assays from isolated mitochondria; comparison with paclitaxel\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution assays with defined peptide domains, single lab\",\n      \"pmids\": [\"15691386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Tat interacts with LIS1, a microtubule-associated protein, in vitro and in vivo. LIS1 was identified during biochemical fractionation of T-cell extracts co-purifying with Tat-associated RNAPII CTD kinase activity. Tat-LIS1 interaction was confirmed by co-IP in HeLa cells and yeast two-hybrid. Tat did not interact directly with CDK7, cyclin H, or MAT1 that co-purify in the same fractions.\",\n      \"method\": \"Biochemical fractionation of T-cell extracts; in vitro binding assay; co-immunoprecipitation from HeLa cells; yeast two-hybrid\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods including co-IP, in vitro binding, and yeast two-hybrid; single lab\",\n      \"pmids\": [\"15698475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HEXIM1 inhibits Tat transactivation by regulating P-TEFb activity; HEXIM1-mediated repression requires both its 7SK snRNA basic recognition motif and the C-terminal region required for cyclin T1 interaction. HEXIM1 expression specifically represses transcription mediated by direct activation of P-TEFb through artificial recruitment of GAL4-CycT1, and this repression is not due to global inhibition of cellular transcription.\",\n      \"method\": \"Co-expression transcriptional repression assays; HEXIM1 domain mutant analysis; GAL4-CycT1 artificial recruitment assay; HIV LTR reporter assays\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional domain mutagenesis with multiple reporter systems, single lab\",\n      \"pmids\": [\"15992410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Tat is required for efficient HIV-1 reverse transcription; HIV-1 virions deleted in tat cannot initiate reverse transcription efficiently in PBMCs, despite containing normal levels of genomic RNA, reverse transcriptase, and other viral proteins. Complementation of tat in producer cells (not target cells) rescues the reverse transcription defect, and tat-deleted virions also show defects in endogenous reverse transcription assays.\",\n      \"method\": \"Tat-deleted HIV-1 virion production; infection of PBMCs with complementation in producer vs. target cells; endogenous reverse transcription assays; protein and RNA quantification of virion components\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic complementation with defined producer/target cell distinction, multiple assays establishing the reverse transcription defect\",\n      \"pmids\": [\"9135139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The structure of HIV-1 Tat protein in solution was determined by 2D NMR and molecular dynamics; the protein exhibits a hydrophobic core of 16 amino acids, a glutamine-rich domain of 17 amino acids, a cysteine-rich domain, and a basic sequence region. The basic and cysteine-rich domains are highly flexible. The C-terminal region contains an RGD loop structurally similar to that of decorsin.\",\n      \"method\": \"2D NMR spectroscopy; molecular dynamics calculations\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure determination with MD validation, single lab but rigorous structural method\",\n      \"pmids\": [\"7723010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HIV-1 Tat (clade B) binds directly to the NMDA receptor (NR1 subunit) leading to excitotoxicity; the Cys30-Cys31 motif in Tat is critical for NMDA receptor activation. Through molecular modeling and site-directed mutagenesis, Cys31 is predicted to disrupt the disulfide bond between Cys744 and Cys798 on NR1 by interacting with Cys744, leaving a free thiol on Cys798 and causing persistent NMDA receptor activation. The Cys31Ser mutation in clade C Tat significantly attenuates neurotoxicity.\",\n      \"method\": \"Direct Tat-NMDA receptor binding experiments; site-directed mutagenesis (Cys31Ser); molecular modeling; neuronal toxicity assays comparing clade B vs. clade C Tat\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assays plus mutagenesis plus functional toxicity; molecular mechanism partly based on modeling\",\n      \"pmids\": [\"19020013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HIV-1 Tat localizes in nucleoli of cells and interacts with fibrillarin and U3 snoRNA (both required for pre-rRNA maturation), leading to impaired processing of ribosomal RNA precursors and decreased cytoplasmic ribosomes.\",\n      \"method\": \"Transgenic Drosophila expressing HIV-1 tat; immunolocalization showing co-localization with fibrillarin in nucleoli; ribosomal rRNA precursor processing assays; co-immunoprecipitation/interaction with fibrillarin and U3 snoRNA\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo localization with co-localization, interaction data, and functional rRNA processing assay; model organism system\",\n      \"pmids\": [\"18559082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tat is secreted by infected CD4+ T-cells through an unconventional pathway that does not involve the endoplasmic reticulum or known intracellular organelles. A Tat chimera with an N-glycosylation site was not glycosylated when expressed in cells but was glycosylated when introduced into purified microsomes, confirming ER-independent secretion. At 16°C, Tat secretion is inhibited and Tat accumulates at the plasma membrane, indicating secretion occurs at the plasma membrane level.\",\n      \"method\": \"N-glycosylation reporter chimera assay; pharmacological inhibitor studies; temperature-block experiments; subcellular fractionation\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches (glycosylation reporter, temperature block, pharmacological inhibitors), single lab\",\n      \"pmids\": [\"19995346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Tat secretion by infected cells requires high-affinity binding to phosphatidylinositol(4,5)bisphosphate (PI(4,5)P2) concentrated in the inner leaflet of the plasma membrane, enabling Tat recruitment and membrane crossing. Following secretion, Tat binds various cell-surface receptors, is endocytosed, and low endosomal pH triggers a conformational change enabling membrane insertion. Translocation to the cytosol is assisted by Hsp90. The single tryptophan residue in Tat is important for membrane insertion.\",\n      \"method\": \"PI(4,5)P2 binding studies; conformational change assays at low pH; Hsp90 inhibition studies; tryptophan mutagenesis\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic experiments but review-style compilation; some findings from referenced primary studies\",\n      \"pmids\": [\"21951552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HIV-1 Tat protein is degraded by the 20S proteasome in an ubiquitin-independent manner (consistent with its intrinsically unfolded nature); curcumin activates the 20S proteasome and promotes dose- and time-dependent Tat degradation without affecting Tat mRNA levels. Proteasomal inhibitor MG132 blocks curcumin-induced Tat degradation. The properly folded HIV-1 Gag protein is not affected by curcumin.\",\n      \"method\": \"Cycloheximide chase assay; proteasome inhibitor (MG132) experiments; semi-quantitative RT-PCR; dose-response degradation assays in HEK-293T cells\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological and biochemical methods establishing proteasomal degradation; single lab\",\n      \"pmids\": [\"27283735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The deubiquitinase USP7 stabilizes HIV-1 Tat protein through deubiquitination; inhibition of USP7 (by P5091 inhibitor or CRISPR-Cas9 deletion) leads to Tat protein degradation and reduced virus production. USP7 overexpression increases Tat-mediated HIV-1 production in a dose-dependent manner. HIV-1 infection up-regulates endogenous USP7 levels in human T-cells.\",\n      \"method\": \"USP7-specific inhibitor (P5091) and general DUB inhibitor (PR-619) treatment; CRISPR-Cas9 USP7 knockout; dose-dependent overexpression assays; western blot analysis; virus production assays in J1.1 latently infected T-cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition plus genetic knockout plus overexpression, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28280111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Tat mRNA can be translated efficiently both in vitro and in cells, likely via an internal ribosome entry site (IRES) mechanism. Tat protein can strongly stimulate translation from its own cognate mRNA in a TAR-dependent fashion, providing a positive feedback loop to ensure sufficient Tat production early in infection.\",\n      \"method\": \"In vitro translation assays; monocistronic and dicistronic reporter RNA constructs with Tat 5'-UTR; cell-based translation assays; TAR deletion/mutation analysis\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro and cell-based reconstitution with defined RNA elements, single lab\",\n      \"pmids\": [\"19671151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Thrombospondin-1 (TSP) binds directly to Tat protein with high affinity (Kd = 25 nM); TSP inhibits cell internalization and HIV-1 LTR trans-activating activity of extracellular Tat (ID50 = 10-30 nM), as well as Tat's mitogenic activity. TSP is ineffective once Tat has already bound to cell-surface heparan sulfate proteoglycans, and TSP prevents but does not disrupt Tat-heparin interaction in vitro.\",\n      \"method\": \"GST-Tat pulldown; Scatchard binding analysis; LTR trans-activation assays; cell internalization assays; heparin-Tat interaction competition assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding measurements with Scatchard analysis plus functional assays; single lab\",\n      \"pmids\": [\"11023976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HIV-1 Tat expression in astrocytes induces lysosomal exocytosis, which is the mechanism of astrocyte-mediated Tat neurotoxicity. Tat-induced lysosomal exocytosis requires GFAP expression and is mediated through ER stress. Two-dimensional gel electrophoresis and mass spectrometry identified elevated lysosomal hydrolytic enzymes and plasma membrane-associated proteins in the conditioned medium of Tat-expressing astrocytes.\",\n      \"method\": \"2D gel electrophoresis and mass spectrometry; lysosomal exocytosis assays; GFAP knockout/knockdown; ER stress pathway analysis; conditioned medium neurotoxicity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal approaches including proteomics, functional exocytosis assays, and genetic manipulation; single lab\",\n      \"pmids\": [\"27609518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Two-pore channels (TPCs) in endolysosomes regulate Tat escape from endolysosomes into the cytosol and subsequent LTR transactivation; pharmacological blocking or knockdown of TPCs attenuates Tat endolysosome escape and LTR transactivation. Chelating endolysosomal or cytosolic calcium also attenuates Tat escape. TRPML1 knockdown has no effect, indicating specificity for TPCs.\",\n      \"method\": \"Pharmacological TPC inhibitors; TPC and TRPML1 siRNA knockdown; calcium chelation (rhodamine-dextran for endolysosomal Ca2+, BAPTA-AM for cytosolic Ca2+); LTR transactivation reporter assays; Tat endolysosome escape imaging assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological plus genetic (siRNA) approaches with appropriate controls (TRPML1 negative control); single lab\",\n      \"pmids\": [\"31950548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Tat-derived peptides (but not full-length Tat protein itself) competitively and reversibly inhibit neprilysin, the major amyloid beta-peptide degrading enzyme in the brain. Both Tat peptides and Tat protein are slowly hydrolyzed by neprilysin, suggesting that proteolytic fragments accumulate and inhibit the enzyme.\",\n      \"method\": \"In vitro inhibition assays with recombinant neprilysin; kinetic analysis (competitive inhibition); comparison of Tat protein vs. Tat-derived peptides\",\n      \"journal\": \"Journal of neurovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic assay with kinetic characterization; single lab, distinguishes peptide fragments from full-length protein\",\n      \"pmids\": [\"16877296\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HIV-1 Tat is a multifunctional viral protein that primarily activates transcriptional elongation from the HIV-1 LTR by binding to TAR RNA (specifically at its bulge region) and recruiting the P-TEFb complex (CDK9/cyclin T1), which hyperphosphorylates the RNA Pol II CTD; this activity is regulated by cycles of acetylation (by p300 at Lys50 and PCAF at Lys28) and deacetylation (by SIRT1), which control Tat's interaction with P-TEFb and TAR RNA respectively; Tat is also required for efficient reverse transcription, stimulates cotranscriptional mRNA capping via direct binding to the capping enzyme Mce1, is secreted unconventionally through the plasma membrane via PI(4,5)P2 binding and escapes endolysosomes via TPC-mediated calcium release, mimics beta-chemokines by binding CCR2 and CCR3 on monocytes, directly interacts with the NR1 subunit of NMDA receptors to cause neurotoxicity, enhances tubulin polymerization, impairs pre-rRNA processing through interaction with fibrillarin/U3 snoRNA in the nucleolus, and is stabilized by the deubiquitinase USP7 or degraded by the 20S proteasome in an ubiquitin-independent manner.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HIV-1 Tat is a multifunctional viral transactivator whose central function is to drive processive transcriptional elongation from the HIV-1 LTR by binding the nascent TAR RNA stem-loop [#0] and converting paused polymerase complexes into elongation-competent ones [#1]. Tat is organized into separable functional modules: an arginine-rich basic domain that binds the single-stranded bulge of TAR with nanomolar affinity [#0], and a distinct activation domain that stimulates processivity even when tethered to RNA through a heterologous binding module [#1]; the activation domain alone also supports transcription when Tat is recruited to promoter DNA, where the RNA-binding domain becomes dispensable [#2]. Mechanistically, Tat recruits the P-TEFb kinase complex (CDK9/cyclin T1) to TAR, and cyclin T1 itself contributes TAR loop recognition to assemble a ternary Tat-cyclin T1-TAR complex that hyperphosphorylates the RNA Pol II CTD [#4], with the cellular elongation cofactor Tat-SF1 and its associated factors SPT5 and the TFIIF subunit RAP30 required for full transactivation [#3, #6]. P-TEFb availability for Tat is constrained by HEXIM1, which represses Tat-dependent transcription via cyclin T1 and 7SK snRNA [#14]. Tat activity is tuned by reversible acetylation: PCAF acetylates Lys28 to enhance P-TEFb binding while p300 acetylates Lys50 to release Tat from TAR during elongation [#5], with the acetyl-Lys50 mark read by the PCAF bromodomain to drive synergistic activation [#9], and SIRT1 deacetylates Tat to recycle it for further rounds of transcription [#11]. Beyond elongation, Tat couples to co-transcriptional mRNA capping through direct binding of its C-terminus to the capping enzyme Mce1 [#10] and is required in producer cells for efficient reverse transcription of progeny virions [#15]. Tat acts extracellularly after unconventional secretion that bypasses the ER and occurs at the plasma membrane via PI(4,5)P2 binding [#19, #20], followed by endocytic uptake and TPC- and calcium-dependent escape from endolysosomes into the cytosol [#26]; extracellular Tat mimics beta-chemokines by binding CCR2 and CCR3 to trigger monocyte calcium flux and migration [#7], and contributes to neurotoxicity through direct engagement of the NMDA receptor NR1 subunit via its Cys30-Cys31 motif [#17]. Tat protein levels are governed post-translationally by ubiquitin-independent 20S proteasomal degradation of the intrinsically unstructured protein [#21] and by USP7-mediated deubiquitination that stabilizes Tat and supports virus production [#22].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established the molecular basis of Tat target recognition by showing Tat binds a specific RNA element rather than acting through DNA alone, defining TAR as the transactivation-response RNA target.\",\n      \"evidence\": \"In vitro RNA-binding with bacterial Tat and synthetic TAR mutants, Scatchard analysis\",\n      \"pmids\": [\"2247474\", \"1903308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not explain why loop mutations abolish activity in vivo despite intact bulge binding in vitro\", \"No cellular cofactor identified for TAR engagement\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Resolved how Tat activates transcription by showing it enhances elongation/processivity rather than initiation, and that RNA-binding and activation functions are modular.\",\n      \"evidence\": \"Domain-swap tethering of Tat activation domains to R17/GAL4 RNA- and DNA-binding modules with LTR reporter assays\",\n      \"pmids\": [\"1658392\", \"1752440\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The cellular elongation machinery recruited by the activation domain was not identified\", \"Mechanism distinguishing RNA- vs DNA-tethered activation unclear\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Provided the first structural framework for Tat, defining its domain architecture and intrinsic flexibility.\",\n      \"evidence\": \"2D NMR spectroscopy and molecular dynamics of recombinant Tat\",\n      \"pmids\": [\"7723010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Flexible basic and cysteine-rich regions limit a defined fold\", \"No structure of Tat bound to TAR or partners\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Revealed a transcription-independent role by showing Tat is required in producer cells for efficient reverse transcription of progeny virions.\",\n      \"evidence\": \"tat-deleted virion production, producer- vs target-cell complementation, endogenous reverse transcription assays in PBMCs\",\n      \"pmids\": [\"9135139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking Tat to reverse transcription unresolved\", \"Whether a virion-incorporated Tat species mediates the effect not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified the cellular cofactor network supporting Tat transactivation, placing Tat within the general elongation machinery.\",\n      \"evidence\": \"Functional complementation cloning of Tat-SF1, reciprocal co-IP with RAP30/hSPT5, immunodepletion/rescue and overexpression assays\",\n      \"pmids\": [\"8849451\", \"9765201\", \"10454543\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect contacts between Tat and Tat-SF1/SPT5 not fully resolved\", \"Stoichiometry within the elongation complex unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the core kinase mechanism by showing Tat recruits P-TEFb (CDK9/cyclin T1) and that cyclin T1 supplies TAR loop recognition, reconciling in vitro binding with in vivo loop requirements.\",\n      \"evidence\": \"Dominant-negative CDK9, kinase inhibitors, ternary complex assays with cyclin T1 and TAR loop mutants\",\n      \"pmids\": [\"10550206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of the Tat-cyclin T1-TAR ternary complex not determined here\", \"How CTD phosphorylation is coupled to downstream elongation factors unspecified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Established acetylation as a regulatory switch by mapping two HAT-specific sites with opposing functional consequences for P-TEFb binding and TAR release.\",\n      \"evidence\": \"In vitro acetylation, Lys28/Lys50 mutagenesis, co-IP and transactivation assays\",\n      \"pmids\": [\"10545121\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo timing/ordering of the two acetylation events during a transcription cycle not resolved\", \"Deacetylation step not yet identified at this stage\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Extended Tat function to the extracellular space by showing it mimics beta-chemokines through CCR2/CCR3 engagement on monocytes.\",\n      \"evidence\": \"Ca2+ flux, migration, cross-desensitization, and competitive receptor-binding/displacement on CCR2/CCR3-transfected cells\",\n      \"pmids\": [\"9789057\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of Tat-CCR2/CCR3 binding undefined\", \"Physiological contribution to pathogenesis in vivo not established\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Implicated Tat in neuronal apoptosis via GSK-3beta but clarified the interaction is indirect.\",\n      \"evidence\": \"GSK-3beta activity assays, co-precipitation, lithium rescue in rat cerebellar granule neurons\",\n      \"pmids\": [\"10428053\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The intermediary linking Tat to GSK-3beta activation is unknown\", \"Co-precipitation without demonstrated direct enzymatic regulation\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified thrombospondin-1 as a high-affinity extracellular regulator that neutralizes Tat uptake and transactivation before cell-surface engagement.\",\n      \"evidence\": \"GST-Tat pulldown, Scatchard analysis, internalization and LTR transactivation assays, heparin competition\",\n      \"pmids\": [\"11023976\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of TSP-Tat antagonism not shown\", \"Single-lab binding characterization\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Connected acetylation to cofactor reading and to a second cotranscriptional step (capping), broadening Tat's elongation coupling.\",\n      \"evidence\": \"Structural analysis of acetyl-Lys50 Tat bound to PCAF bromodomain with mutagenesis; in vitro cotranscriptional capping assays defining the C-terminal Tat-Mce1 interaction\",\n      \"pmids\": [\"12032084\", \"12408826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Capping data are single-lab in vitro reconstitution\", \"How bromodomain reading is temporally integrated with TAR release unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Completed the acetylation cycle by identifying SIRT1 as the deacetylase that recycles Tat for repeated transcription rounds, and added microtubule, mitochondrial, and LIS1 connections.\",\n      \"evidence\": \"In vitro deacetylation, co-IP, SIRT1-null MEF rescue; tubulin polymerization and mitochondrial cytochrome c assays; biochemical fractionation/co-IP/Y2H for LIS1\",\n      \"pmids\": [\"15719057\", \"15691386\", \"15698475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of Tat-LIS1 and tubulin effects for infection vs neurotoxicity unclear\", \"Tubulin/mitochondrial findings are single-lab in vitro\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined a negative regulatory arm of P-TEFb availability constraining Tat function.\",\n      \"evidence\": \"HEXIM1 domain-mutant repression assays and GAL4-CycT1 artificial recruitment with LTR reporters\",\n      \"pmids\": [\"15992410\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dynamics of HEXIM1/7SK release to license Tat not resolved here\", \"Single-lab functional assays\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established direct receptor- and organelle-level mechanisms of Tat neurotoxicity and effects on ribosome biogenesis.\",\n      \"evidence\": \"Direct Tat-NR1 binding with Cys31Ser mutagenesis and clade comparison; transgenic Drosophila nucleolar localization with fibrillarin/U3 snoRNA interaction and rRNA processing assays\",\n      \"pmids\": [\"19020013\", \"18559082\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NMDA receptor mechanism partly modeling-based\", \"rRNA processing effect shown in a model organism system\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined the unconventional secretion route, showing Tat exits at the plasma membrane via PI(4,5)P2 binding independent of the ER.\",\n      \"evidence\": \"N-glycosylation reporter chimera, temperature-block, fractionation; PI(4,5)P2 binding, low-pH conformational change and Hsp90/tryptophan studies\",\n      \"pmids\": [\"19995346\", \"21951552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular machinery driving membrane crossing not fully reconstituted\", \"Some mechanistic claims compiled review-style\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined post-translational control of Tat abundance and a lysosome-based neurotoxic mechanism.\",\n      \"evidence\": \"Cycloheximide chase, MG132 and curcumin-induced 20S degradation assays; GFAP-dependent lysosomal exocytosis with proteomics and ER stress analysis in astrocytes\",\n      \"pmids\": [\"27283735\", \"27609518\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous physiological trigger of 20S degradation unspecified\", \"Astrocyte exocytosis pathway is single-lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified USP7 as a deubiquitinase that stabilizes Tat and promotes virus production, complementing ubiquitin-independent turnover.\",\n      \"evidence\": \"P5091 inhibition, CRISPR USP7 knockout, dose-dependent overexpression, and virus production assays in latently infected T-cells\",\n      \"pmids\": [\"28280111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The ubiquitin ligase opposing USP7 not identified\", \"Reconciliation with ubiquitin-independent 20S degradation unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved how extracellular Tat reaches the cytosol by implicating two-pore channels and endolysosomal calcium in endolysosome escape.\",\n      \"evidence\": \"TPC pharmacological inhibitors and siRNA, calcium chelation, TRPML1 negative control, and LTR transactivation/escape imaging assays\",\n      \"pmids\": [\"31950548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular interaction between Tat and TPC machinery not established\", \"Single-lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the many Tat activities — elongation, capping, reverse transcription, secretion/uptake, and the multiple neurotoxic and immunomodulatory extracellular functions — are temporally and spatially coordinated within an infection, and how the opposing degradation (20S) and stabilization (USP7) pathways set Tat levels in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated structural model of the Tat-P-TEFb-TAR-cofactor elongation complex\", \"The ubiquitin ligase and physiological signals governing Tat turnover are unidentified\", \"In vivo contribution of extracellular Tat functions to pathogenesis not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 5, 10]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [12, 13]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 6]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [19, 20]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [20, 26]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [7, 19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [10, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [15, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"complexes\": [\"P-TEFb (CDK9/cyclin T1)\"],\n    \"partners\": [\"CCNT1\", \"CDK9\", \"TATSF1\", \"SUPT5H\", \"EP300\", \"KAT2B\", \"SIRT1\", \"USP7\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}